Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with nimotuzumab + vinorelbine in childhood diffuse intrinsic pontine glioma
2024-513654-30-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab and vinorelbine in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Best response rate up to week 36. Planned start Jun 2024; status: authorised.
02
Drugs
nimotuzumabvinorelbine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on 2024-513654-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513654-30-00.